Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 11/8/22 → 03/21/24 |
Funding
- AstraZeneca Pharmaceuticals LP: $18,750.00
AstraZeneca AB: A Randomised, Double-blind, Placebo-controlled, Multi-center, Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for up to 48 Weeks in Participants with Heart Failure with Left
- Skopicki, Hal (PI)
- Tam, Edlira (CoPI)
- Bloom, Michelle (CoPI)
Project: Research